Pilocytic astrocytoma (WHO grade I) is a circumscribed, slowly growing, benign astrocytoma that most frequently develops in the cerebellar hemispheres and in midline structures and occurs predominantly in childhood and adolescence. In contrast to diffusely infiltrating gliomas in adults (e.g. grade II astrocytomas, oligodendrogliomas), survival of patients with pilocytic astrocytoma is excellent after surgical intervention. To search for potential molecular mechanisms underlying its benign biologic behavior, we compared gene expression profiles of pilocytic astrocytomas (8 cases) with those of normal cerebellum (4 cases), low-grade astrocytomas (WHO grade II; 15 cases), and oligodendrogliomas (WHO grade II; 17 cases) by cDNA array analysis. A number of immune system-related genes such as HLA-DRa, HLA-DPB1, HLA-DQB1, IgG3, IgGK, FCER1G, A2M, FCRN, IFI-56K, and DAP12 were upregulated in pilocytic astrocytomas relative to normal cerebellum, grade II astrocytomas, and oligodendrogliomas. Genes expressed at higher levels in pilocytic astrocytomas than in grade II astrocytomas and oligodendrogliomas include HLA-DRa, HLA-DPA1, HLA-DPB1, HLA-DQB1, A2M, TIMP1, TIMP2, CDKN1A, and SOCS3 and those expressed at lower levels include EGFR and PDGFRA. Hierarchical clustering analysis using the entire set of 1176 genes distinguished pilocytic astrocytomas from grade II astrocytomas and oligodendrogliomas. Clustering analysis using selected subgroups of genes based on their molecular functions revealed that immune system-related genes (75 genes) or cell adhesion, migration, and angiogenesis-related genes (69 genes) showed similar power to the entire gene set for separation of pilocytic astrocytomas from diffusely infiltrating low-grade gliomas. Immunohistochemistry revealed that HLA-DRa is expressed diffusely in neoplastic cells in pilocytic astrocytomas, whereas in oligodendrogliomas, expression was limited to scattered reactive astrocytes. These results suggest that gene expression profiles of pilocytic astrocytomas differ significantly from those of diffusely infiltrating low-grade gliomas and that their benign biologic behavior may be related to upregulation of immune defense-associated genes.
INTRODUCTION
Pilocytic astrocytoma (WHO grade I) is a circumscribed, slowly growing, benign astrocytoma, which occurs predominantly in childhood and adolescence (1) . Although any location of the brain may be involved, the tumor arises most frequently in the cerebellar hemispheres and in midline structures such as the hypothalamus and optic tract (1) .
In contrast to low-grade astrocytoma (WHO grade II), which frequently progresses to anaplastic astrocytoma (WHO grade III) and glioblastoma (WHO grade IV), pilocytic astrocytomas rarely progress to more malignant histologic types (2) . More than 80% of patients with a pilocytic astrocytoma survive for more than 10 years after surgical intervention with or without radiation therapy (3, 4) .
Little is known about the molecular mechanisms of pathogenesis of pilocytic astrocytomas. Some cases are associated with neurofibromatosis type 1 (NF1) with NF1 germline mutations (1, 5) , but these are very rare, the prevalence of NF1 in most populations being 1:4000 (6) . Approximately 20% of pilocytic astrocytomas, including NF1 cases, show loss of 17q, a region that includes the NF1 gene (7) . However, no NF1 mutations were observed among 16 pilocytic astrocytomas (8) . In a study using comparative genomic hybridization, a considerable variety of chromosomal imbalances, most frequently with gains and deletions on chromosome 19 and gains on chromosome 22, were observed (9), whereas another comparative genomic hybridization study showed no specific cytogenetic abnormalities in 48 pilocytic astrocytomas, including 7 adult cases (10) . TP53 mutations in exons 5 to 8 were either absent or very rare (11) (12) (13) (14) . An exception was the finding by Hayes et al (15) of TP53 mutations in 7 of 20 (35%) pilocytic astrocytomas, predominantly in exon 4; however, this has not been confirmed by other studies.
By expression profiling of 21 pilocytic astrocytomas, Wong et al (16) found that a number of genes involved in neurogenesis, cell adhesion, synaptic transmission, central nervous system development, potassium ion transport, protein dephosphorylation, and cell differentiation were significantly deregulated in pilocytic astrocytomas in comparison to normal cerebellum. Gutmann et al (17) reported that gene expression profiles of pilocytic astrocytomas (6 sporadic and 2 NF1-associated cases) were closer to those of astrocytic cells and identified a number of genes that were differentially expressed in pilocytic astrocytomas relative to all other tissue types (cyclin D2 and ApoD) relative to astrocytic cell lines and oligodendroglioma (GAP43, connexin-43, ezrin, and integrin a-7) or relative to astrocytic cell lines (N-CAM, L1-CAM, and syndecan). Hunter et al (18) showed that ApoD, Sparc, L1-CAM, LRP, SEMA3E, and HLA-DPA1 were expressed at higher levels and EGFR, cathepsin H, and nuclear receptor subfamily 1 were expressed at lower levels in pilocytic astrocytoma than in anaplastic astrocytoma. Rickman et al (19) compared expression profiles of 19 pilocytic astrocytomas with those of 6 normal brain tissue samples, 5 grade II astrocytomas, and 21 glioblastomas and found a large number of genes that were differentially expressed between these tumor subtypes. However, the molecular basis of the benign biologic behavior of pilocytic astrocytomas has not been fully elucidated.
In the present study, we used a cancer-related cDNA array to directly compare gene expression profiles of pilocytic astrocytomas (8 cases) with those of normal brain tissue (4 postmortem normal cerebella), grade II astrocytomas (15 cases), and oligodendrogliomas (WHO grade II, 17 cases) to identify typically up-or downregulated genes that may be implicated in the benign biologic behavior of pilocytic astrocytomas.
MATERIALS AND METHODS

Tumor Samples
Frozen tissue from 8 pilocytic astrocytomas (WHO grade I) was obtained from the Department of Neuropathology, University Hospital Zurich, Switzerland. The mean age of patients with pilocytic astrocytoma was 11.1 6 5.1 years (range, 3-17 years). Two patients were males and 6 were females. Five tumors occurred in the cerebellum, 2 in the optic nerve, and one in the mesencephalon. The 15 grade II astrocytomas and 17 oligodendrogliomas (WHO grade II) have been described previously (20) . Four nontumorous postmortem (within 7 hours after death) samples of cerebellum were also obtained from the Department of Neuropathology, University Hospital Zurich, Switzerland. All samples were snapfrozen after surgical removal and stored at 280°C until use. A Universal Human Reference RNA derived from 10 different human cell lines (Stratagene, La Jolla, CA) was also profiled and used as a reference in preparing data for clustering analysis.
cDNA Array Experiment and Hierarchical Clustering Analysis
The same protocols and methods have been used and details were published previously (20, 21) . Briefly, an Atlas Human Cancer 1.2 Array (BD Clontech, Palo Alto, CA) was hybridized with a 32 P-labeled cDNA probe made from 5 mg of total RNA. After washing, the hybridization signal was captured on Kodak Biomax MS X-ray film and scanned. Data quantitation and comparison were performed using the AtlasImage 2.01 software (BD Clontech) (21) . For direct comparison between tumor subtypes or between tumor and nontumorous tissues, averaged arrays for pilocytic astrocytomas, oligodendrogliomas, grade II astrocytomas, and nontumorous tissues were generated, respectively. For data preparation for clustering analysis, the signal intensity of each gene on each array (including all normal and tumor samples) was compared with that of a Universal Human Reference RNA array. To reduce spuriously large change indices, genes with an adjusted intensity below 10% of the background level were set to a value of 10% of the background intensity. Hierarchical clustering analysis was performed using the GeneCluster/TreeView software (http://rana.lbl.gov). The intensity ratio (sample/reference) obtained in data preparation was entered into the GeneCluster program, log 2 -transformed, median-centered, and normalized before being subjected to average linkage clustering.
Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction
First-strand cDNA was synthesized using 1 mg of DNasetreated total RNA as previously described (20, 21) . Real-time quantitative polymerase chain reaction (PCR) was performed using a SYBR Green QPCR Master mix from Stratagene on an Mx3000 Instrument (Stratagene). The protocol used was as follows: one cycle of denaturation at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 30 seconds, annealing at 57°C for 1 minute, and extension at 72°C for 30 seconds. To verify the specificity of the PCR product, one cycle of 95°C for 1 minute, 55°C for 30 seconds, and 95°C for 30 seconds was added immediately after the previous 40 cycles of PCR reaction and the dissociation curve was monitored in a continuous fashion. The reaction consisted of 6.25 mL of 23 SYBR Green Mix, 2 mL of forward and reverse primers (final concentrations 160 nM) and 1 mL of pooled cDNA in a total volume of 12.5 mL per well. Primer sequences were as follows: 5#-GCC AAC TTG GAA ATC ATG ACA-3# (sense) and 5#-AGG GCT GTT CGT GAG CAC A-3# (antisense) for HLA-DRa; 5#-ACA CTC AGG CCA CCA ACG AT-3# (sense) and 5#-GAG GGC ACA AAG GTC AGG TA-3# (antisense) for HLA-DPa1; 5#-ACA GAT TTC TAC CCA GGC AGC AT-3# (sense) and 5#-CCC CCA GCT CCC GTC AAT GTC TT-3# (antisense) for HLA-DPb1; 5#-CAC TGT GAG CGC AGA GGC ACT AGA-3# (sense) and 5#-CTA ATA TGT CTC CCA AAA CTG A-3# (antisense) for A2M; 5#-CTC ACG CAG TTG GGC ACT TT-3# and 5#-CCA CCT CAC AGT TAT TGA ACA TCC T-3# for EGFR; 5#-TCG GAC CAG CGC CAC TTC T-3# and 5#-CCC CCG GAG TAG ATG TAA T-3# for SOCS3; 5#-CTG TTG TTG CTG TGG CTG AT-3# (sense) and 5#-GCG GGG GTG TAG ACG AA-3# (antisense) for TIMP1; and 5#-CAA CCG CGA GAA GAT GAC C-3# (sense) and 5#-TCC AGG GCG ACATAG CACA-3# (antisense) for b-actin. The comparative Ct method (PE Applied Biosystems) was used to calculate the relative gene expression levels between tumor types.
HLA-DRa Immunohistochemistry
HLA-DRa immunohistochemistry was performed on formalin-fixed, paraffin-embedded sections, including 15 cases of pilocytic astrocytoma, 16 cases of grade II astrocytoma, and 19 cases of oligodendroglioma. Sections were deparaffinized in xylene and rehydrated in graded ethanol. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol for 30 minutes at room temperature. Sections were then put in a cooker with hot antigen unmasking solution Vector H 3300 (Vector Laboratories, Burlingame, CA), left to boil for 10 minutes, and then cooled down for 60 minutes. After incubation with 5% skim milk for 1 hour, sections were incubated overnight at 4°C with one of 2 alternative primary monoclonal HLA-DRa antibodies (one from DakoCytomation, Glostrup, Denmark, antigen, 33 kDa alpha-chain subunit HLA-D products prepared from the B lymphoblastoid cell line Bristol 8, diluted at 1:150; and another from Abcam Ltd., Cambridge, U.K., antigen, Bristol 8 separated alpha chain preparation, diluted at 1:600). The reaction was visualized using Vectastain Elite ABC kit (Vector Laboratories) and 3, 3#-diaminobenzidine solution (Vector Laboratories). Sections were then counterstained with hematoxylin. Sections without primary antibody served as negative controls, whereas a formalin-fixed, paraffin-embedded section of a human tonsil, prepared in the same way, was used as a positive control.
GFAP Immunohistochemistry
For GFAP immunohistochemistry, a monoclonal antibody to GFAP (DakoCytomation) was used at 1:400 (overnight incubation at 4°C) without antigen retrieval. The reaction was visualized using Vectastain Elite ABC kit (Vector Laboratories) and 3,3#-diaminobenzidine solution (Vector Laboratories). Sections were then counterstained with hematoxylin.
RESULTS
Comparison of Gene Expression Profiles Between Pilocytic Astrocytomas and Normal Cerebellum
Gene expression profiles of 8 pilocytic astrocytomas and 4 nontumorous samples of cerebellum were obtained by cDNA probe hybridization to Atlas Human Cancer 1.2 Arrays (BD Clontech). Comparison of gene expression profiles was performed using the AtlasImage 2.01 software (BD Clontech).
Preliminary comparison between subgroups of pilocytic astrocytomas from different locations (i.e. cerebellum, optic nerve, and mesencephalon) did not show any significant difference in gene expression profiles. We therefore generated an averaged array for all the 8 pilocytic astrocytomas and one array for the 4 normal cerebellum tissue samples. Significant differences in expression profiles were evident. Applying a cutoff threshold at an intensity ratio of $ 2 or # 0.5 and an absolute intensity difference of $ 2500, we identified 97 genes that showed higher expression and 114 genes that showed lower expression in pilocytic astrocytomas relative to normal cerebellum. Some of these genes are listed in Table 1 . Notably, a number of immune system-related genes such as HLA-DRa, HLA-DPB1, HLA-DQB1, IgG3, IgGK, FCER1G, A2M, FCRN, IFI-56K, and DAP12 were upregulated in pilocytic astrocytomas. Hierarchical clustering analysis separated all 8 pilocytic astrocytomas from the 4 normal tissue samples (Fig. 1) .
Comparison of Gene Expression Profiles Among Pilocytic Astrocytomas, Grade II Astrocytomas, and Oligodendrogliomas
We generated averaged arrays from 8 pilocytic astrocytomas, 15 grade II astrocytomas, and 17 oligodendrogliomas, respectively, and performed direct comparison. The results on comparison of grade II astrocytomas and oligodendrogliomas have recently been published (20) . With the same cutoff threshold (i.e. an intensity ratio of $ 2 or # 0.5 and an absolute intensity difference of $ 2500), there were 129 genes showing higher expression and 32 genes showing lower expression in pilocytic astrocytomas than in grade II astrocytomas, and 137 genes showing higher expression and 41 lower expression in pilocytic astrocytomas than in oligodendrogliomas. Genes that were differentially expressed between pilocytic astrocytomas and grade II astrocytomas or oligodendrogliomas can be roughly grouped into several functional categories: 1) immune response and defense including HLA-DRa, HLA-DPB1, HLA-DQB1, DAP12, A2M, IFI-56K, IgG3, IgGK, FCER1G, MAD3, BSF2, FCRN, and TAPASIN; 2) cell adhesion, migration and angiogenesis, including TIMP1, TIMP2, MMP14, VEGFR1, COL1A2, COL2A1 and PCDH43; 3) cell growth and transformation, cell-cycle control and apoptosis, including CDKN1A, CCND3, GADD45, GADD153, PDGFRA, EGFR, IGFBP5, SOCS3, GDNPF, and transcription factor AP-1; and 4) DNA repair, structure and replication, and others ( Table 1) .
Distinction of Glioma Subtypes by Hierarchical Clustering Analysis
We first performed hierarchical clustering analysis using the entire set of 1176 genes present on the array. In analyses either including all 3 subtypes or including only pilocytic astrocytoma versus grade II astrocytoma, or pilocytic astrocytoma versus oligodendroglioma, all 8 pilocytic astrocytomas were always clustered together and distinguishable from the majority of grade II astrocytomas or oligodendrogliomas (Fig. 2) , whereas grade II astrocytoma and oligodendroglioma were not separated from each other, as previously reported (20) .
On the array, we further selected several subgroups of genes according to their potential functions and involvement in different biologic processes. These are immune response and defense-related genes (75 genes), cell adhesion, migration, and angiogenesis-related gene (69 genes), p53-related genes (44 genes), cell-cycle-related genes, including p53-related genes (100 genes), apoptosis-related genes (83 genes), and randomly selected genes (70 genes).
Clustering analyses revealed that immune systemrelated genes (Fig. 3a-c) or cell adhesion, migration, and angiogenesis-related genes (Fig. 3d-f ) allowed separation of pilocytic astrocytoma from grade II astrocytoma and oligodendroglioma, these subsets of genes having similar power for separation to the whole set of genes. Analysis using p53-related genes or cell-cycle-related genes also separated the majority (7 of 8) of pilocytic astrocytomas from grade II astrocytomas (data not shown), but not from oligodendrogliomas (data not shown). Clustering using 83 apoptosisrelated genes or 70 randomly selected genes did not distinguish q 2005 American Association of Neuropathologists, Inc. between any 2 subtypes (data not shown). The results of the clustering analyses are summarized in Table 2 .
Confirmation of mRNA Expression Regulation by Real-Time Quantitative Reverse Transcriptase-Polymerase Chain Reaction
To confirm the cDNA array data, we performed real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for 6 genes. In addition, HLA-DPA1 was reported in a recent study to be overexpressed in pilocytic astrocytomas compared with anaplastic astrocytomas by microarray analysis (18) and was also included in our quantitative RT-PCR analyses. Pooled cDNAs for normal cerebellum, grade II astrocytoma, oligodendroglioma, and pilocytic astrocytoma were obtained by combining equal amounts of cDNAs synthesized individually from 5 normal cerebellum samples (of which 4 were used in cDNA array experiments), 18 grade II astrocytomas (15 used in cDNA array experiments), 18 oligodendroglioma (17 used in cDNA array experiments), and 10 pilocytic astrocytoma (8 used in cDNA array experiments). b-Actin was used as internal control in PCR amplification, and the comparative Ct method was used for relative quantification of expression. The results obtained by real-time PCR were consistent with those observed in cDNA array experiments. We thus confirmed upregulation of HLA-DRa, HLA-DPAı, HLA-DPBı A2M, TIMP1, and SOCS3 and downregulation of EGFR in pilocytic astrocytoma relative to grade II astrocytoma, oligodendroglioma, and normal cerebellum (Table 3) .
HLA-DRa Protein Expression
HLA-DRa expression detected by antibody (DakoCytomation) was diffusely observed in the majority of neoplastic cells (. 50%) in 12 of 15 (80%) pilocytic astrocytomas analyzed, whereas expression in . 50% of neoplastic cells was observed in only 4 of 16 (25%) of the grade II astrocytomas analyzed ( Fig. 4; Table 4 ). HLA-DRa immunoreactivity was observed typically in the cytoplasm around the nuclei of neoplastic astrocytes. In oligodendrogliomas, HLA-DRa immunoreactivity was detected in , 10% of neoplastic oligodendroglioma cells in 18 of 19 (95%) cases analyzed. Most cells immunoreactive for HLA-DRa in oligodendrogliomas were scattered reactive astrocytes within the tumor. Immunohistochemistry using another HLA-DRa antibody (Abcam Ltd.) gave similar results (data not shown).
In nontumorous cerebrum and cerebellum, HLA-DRa expression was occasionally observed in scattered astrocytes. GFAP immunohistochemistry demonstrated that these were reactive astrocytes (Fig. 4) .
Human tonsil was used as a positive control and showed immunoreactivity to HLA-DRa in the cell membranes of lymphocytes in lymphoid follicles and in both cell membrane and cytoplasm of dendritic cells (Fig. 4) (22) . Sections without primary antibody served as negative controls and were completely negative.
DISCUSSION
Clustering analysis using the entire set of 1176 genes present on the array distinguished pilocytic astrocytoma from grade II astrocytoma and oligodendroglioma (Fig. 2) , whereas grade II astrocytoma and oligodendroglioma were not separable (20) , indicating that patterns of gene expression in pilocytic astrocytoma are significantly different from those of grade II astrocytoma and oligodendroglioma. Further clustering analysis using functional groups of genes showed that 75 genes involved in immune defense, or 69 genes involved in cell adhesion, migration, and angiogenesis, had similar power of separation to the entire set of 1176 genes, suggesting the importance of these categories of genes in separating pilocytic astrocytomas from grade II astrocytomas and oligodendrogliomas (Fig. 3) . A subset of 44 p53-related genes or set of 100 cell-cycle genes also distinguished the majority of pilocytic astrocytoma from grade II astrocytoma, but not from oligodendroglioma. This result is not surprising, considering that the TP53 pathway is frequently altered by TP53 mutations in grade II astrocytomas (. 70%) (20, 21) , whereas pilocytic astrocytomas and oligodendrogliomas both have very low mutation rates (, 10%) of this gene (11) (12) (13) (14) 20) .
Direct comparison showed that 211, 161, and 178 genes had significantly differential expression (with intensity ratios $ 2 or # 0.5 and absolute intensity difference $ 2500) between pilocytic astrocytoma and normal cerebellum tissue, pilocytic astrocytoma and grade II astrocytoma, or pilocytic astrocytoma and oligodendroglioma, respectively, whereas only 79 genes were differentially expressed between grade II astrocytoma and oligodendroglioma (20) . Between pilocytic astrocytomas and other tumors or normal brain tissue, significantly differential expression was seen in a number of genes involved in immune defense, as well as those in cell adhesion, migration, and angiogenesis (Table 1) . Note that a number of immune system-related genes such as HLA-DRa, HLA-DPB1, HLA-DQB1, A2M, FCER1G, DAP12, and FCRN, and angiogenesis/invasion-related genes such as TIMP1 and TIMP3 were grouped in the same node and were upregulated in pilocytic astrocytomas (Table 1) . Analysis including only PA and Oligo (c, f). Note that this analysis showed similar power of separation to the analysis with the whole set of 1176 genes (Fig. 2) . 
In colon, cervix, larynx, and breast tissues, the majority of premalignant lesions acquire de novo HLA class II expression or increase their expression. In all these cases, the HLA-DR changes appeared to be independent of leukocytic infiltration and cytokine induction (23) . Recent data support the role of HLA-DR antigens as a marker of host immune responsiveness against malignant cells, and the prognostic significance of HLA-DR expression in several tumor types is being investigated (25) . In endometrial carcinomas, high immune responsiveness as indicated by high expression of HLA-DRa was found mostly in early-stage tumors (25) . HLA class II antigen expression has been related to good prognosis for squamous cell carcinomas of the larynx (26), breast carcinomas (27) , and large bowel carcinomas (28), whereas HLA-DR positivity was associated with poor prognosis (29) or showed no correlation with prognosis for malignant melanoma (30). Feinmesser et al (31) reported that HLA-DR and beta 2 microglobulin expression detected by immunohistochemistry were most prominent in medullary carcinoma of the breast (which has a relatively favorable prognosis), followed by atypical medullary carcinoma (which has a prognosis closer to that of regular invasive duct carcinoma) and invasive duct carcinoma with and without lymphocytic infiltrates, suggesting that relatively favorable prognosis of medullary carcinoma of the breast may be related to effective tumor antigen presentation to the immune system through MHC-I and MHC-II expression (23, 32) .
In the present study, we found higher expression of HLA-DRa, HLA-DPB1, and A2M by cDNA array in pilocytic astrocytoma compared with grade II astrocytoma and oligodendroglioma, and these findings were confirmed by real-time quantitative RT-PCR. HLA-DPA1 has been previously found by Hunter et al (18) to be overexpressed in pilocytic astrocytoma compared with anaplastic astrocytoma in microarray analysis. By real-time quantitative RT-PCR, we also found significantly higher RNA expression of this gene in pilocytic astrocytoma than in grade II astrocytoma or oligodendroglioma. Furthermore, we demonstrated by immunohistochemistry that HLA-DRa is diffusely expressed in neoplastic cells themselves in pilocytic astrocytomas, and this overexpression of HLA-DRa is not the result of increased numbers of infiltrating microphages or lymphocytes within the tumor. Similar observations of no correlation between lymphocyte infiltration and HLA-DR expression have previously been reported for gliomas by Rossi et al (33, 34) and for meningiomas by Ohara et al (35) . The classic role of MHC class II molecules is to form a complex with tumor antigens and to present it to the antitumor CD41 ''helper'' T cells, which in turn have a classic role as facilitating cells for evolving antitumor CD81 T cell response and for IgG immunoglobulin development. However, CD41 T cells may also be capable of functioning as direct antitumor killer cells in tumors expressing MHC class II antigen (32) . Thus, enhanced HLA class II expression in tumor cells themselves may have significance in tumor immunogenicity, probably through enhanced direct tumor cell killing.
A2M is a protease inhibitor and cytokine transporter and plays a role in proteolysis as well as in cellular immunity and defense. A2M has been reported to be implicated in Alzheimer disease as a result of its ability to mediate the clearance and degradation of A-beta, the major component of beta-amyloid deposits (36, 37) . Recently, the concentration of transformed A2M was found to be increased in patients with multiple sclerosis (38) . The role of A2M in glioma development is currently unknown. The significance of A2M upregulation in pilocytic astrocytomas remains to be elucidated.
Many genes involved in cell adhesion, migration, and angiogenesis were also differentially expressed. Pilocytic astrocytoma is a highly vascular tumor, as is evidenced by its contrast enhancement (1) . In agreement with these histologic observations, we found in the present study that levels of expression of some angiogenesis-associated genes such as VEGFR1, FGFR1, and MMP14 were high in pilocytic astrocytomas (Table 1) . On the other hand, several negative regulators of the same processes were also upregulated. For example, TIMP1 was expressed at an approximately 50-fold higher level in pilocytic astrocytomas than in grade II astrocytoma or oligodendroglioma by both cDNA array and realtime PCR analyses (Table 3) . TIMP2 was also expressed at a higher level (3-to 5-fold) in pilocytic astrocytoma (Table 1 ). TIMP1 and TIMP2 are known inhibitors of metalloproteinases (MMPs), which are positive regulators of tumor cell migration and invasion. Downregulation of TIMPs has been suggested to contribute significantly to the invasive potential of human glioblastomas and anaplastic astrocytomas (39) . An invasive human astrocytoma cell line transfected with a full-length TIMP1 cDNA showed significantly lower invasiveness compared with controls (40) . Thus, upregulated expression of TIMPs might counteract the angiogenic activity and contribute to the absence of significant invasiveness in pilocytic astrocytomas in contrast to the infiltrating capacity seen in grade II diffuse astrocytomas.
PDGFRA and EGFR are known to play important roles in various signaling pathways and can promote cellular transformation (41, 42) . In brain tumors, overexpression of PDGFRA has been reported in grade II astrocytomas (21) and has been related to tumor progression (43) . EGFR amplification and overexpression have also been reported in various tumors such as breast and brain tumors, especially in primary glioblastomas (21, 42) . Our previous study (21) also showed upregulation of EGFR, to a lower extent, in grade II astrocytomas. The much lower level of PDGFRA (approximately 4-to 5-fold less) and EGFR (25-fold less) in pilocytic astrocytoma compared with grade II astrocytoma or oligodendroglioma would be a favorable marker for its prognosis.
In summary, the present study identified a number of genes having significantly differential expression between pilocytic astrocytomas versus normal cerebellum, grade II astrocytoma, or oligodendroglioma. Two subgroups of genes, which are involved in cellular immune response and defense, and in cell adhesion/migration and angiogenesis, respectively, were found to be particularly important in the distinction between tumor subtypes; and their differential expression may 
